Terns Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: TERN · Form: DEF 14A · Filed: Apr 25, 2024 · CIK: 1831363
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Stockholders, Online Meeting, Corporate Governance
TL;DR
<b>Terns Pharmaceuticals, Inc. will hold its 2024 Annual Meeting of Stockholders online on June 10, 2024, urging shareholders to vote by proxy.</b>
AI Summary
Terns Pharmaceuticals, Inc. (TERN) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. The 2024 Annual Meeting of Stockholders for Terns Pharmaceuticals, Inc. will be held online on June 10, 2024, at 9:00 a.m. Pacific Time. Stockholders are urged to vote and submit their proxy via the internet, phone, or mail. Attendance and voting will be conducted electronically via www.meetnow.global/TERN2024. The meeting is being held entirely online to enhance participation, communication, and cost savings. Amy Burroughs, CEO and Director, signed the invitation to the meeting.
Why It Matters
For investors and stakeholders tracking Terns Pharmaceuticals, Inc., this filing contains several important signals. The shift to an online format aims to increase stockholder participation and reduce costs associated with a physical meeting. The proxy statement provides details on the business to be conducted, emphasizing the importance of shareholder representation regardless of attendance.
Risk Assessment
Risk Level: — Terns Pharmaceuticals, Inc. shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.
Analyst Insight
Stockholders should review the proxy materials to understand the proposals and vote their shares accordingly before the June 10, 2024 meeting.
Key Numbers
- June 10, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders.)
- 9:00 a.m. Pacific Time — Annual Meeting Time (Time of the 2024 Annual Meeting of Stockholders.)
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — Registrant and filer of the proxy statement.
- Amy Burroughs (person) — Chief Executive Officer and Director of Terns Pharmaceuticals, Inc.
- June 10, 2024 (date) — Date of the Annual Meeting of Stockholders.
- 2024 (date) — Year of the Annual Meeting of Stockholders.
FAQ
When did Terns Pharmaceuticals, Inc. file this DEF 14A?
Terns Pharmaceuticals, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 25, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Terns Pharmaceuticals, Inc. (TERN).
Where can I read the original DEF 14A filing from Terns Pharmaceuticals, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Terns Pharmaceuticals, Inc..
What are the key takeaways from Terns Pharmaceuticals, Inc.'s DEF 14A?
Terns Pharmaceuticals, Inc. filed this DEF 14A on April 25, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for Terns Pharmaceuticals, Inc. will be held online on June 10, 2024, at 9:00 a.m. Pacific Time.. Stockholders are urged to vote and submit their proxy via the internet, phone, or mail.. Attendance and voting will be conducted electronically via www.meetnow.global/TERN2024..
Is Terns Pharmaceuticals, Inc. a risky investment based on this filing?
Based on this DEF 14A, Terns Pharmaceuticals, Inc. presents a moderate-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.
What should investors do after reading Terns Pharmaceuticals, Inc.'s DEF 14A?
Stockholders should review the proxy materials to understand the proposals and vote their shares accordingly before the June 10, 2024 meeting. The overall sentiment from this filing is neutral.
How does Terns Pharmaceuticals, Inc. compare to its industry peers?
Terns Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutics.
Are there regulatory concerns for Terns Pharmaceuticals, Inc.?
This filing is a standard proxy statement (DEF 14A) required by the SEC for public companies holding annual shareholder meetings.
Industry Context
Terns Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutics.
Regulatory Implications
This filing is a standard proxy statement (DEF 14A) required by the SEC for public companies holding annual shareholder meetings.
What Investors Should Do
- Review the proxy statement for details on proposals to be voted on.
- Submit proxy votes via internet, phone, or mail before the meeting.
- Attend the virtual Annual Meeting on June 10, 2024, to participate and vote electronically.
Key Dates
- 2024-06-10: Annual Meeting of Stockholders — Key date for shareholders to participate in corporate decisions and governance.
Year-Over-Year Comparison
This is the initial filing for the 2024 Annual Meeting of Stockholders.
Filing Stats: 4,727 words · 19 min read · ~16 pages · Grade level 11.5 · Accepted 2024-04-25 16:05:53
Key Financial Figures
- $0.0001 — securities are shares of common stock, $0.0001 par value per share (the “common
Filing Documents
- tern-def14a-2024.htm (DEF 14A) — 774KB
- img192746612_0.jpg (GRAPHIC) — 644KB
- img192746612_1.jpg (GRAPHIC) — 644KB
- img192746612_2.jpg (GRAPHIC) — 644KB
- img192746612_3.jpg (GRAPHIC) — 215KB
- img192746612_4.jpg (GRAPHIC) — 240KB
- 0000950170-24-048289.txt ( ) — 4059KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 22 DIRECTOR COMPENSATION 34
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 37 SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE 39 ADDITIONAL INFORMATION 40 TERNS PHARMACEUTICALS, INC. 1065 East Hillsdale Blvd., Suite 100 Foster City, CA 94404 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS IMPORTANT NOTICE REGARDING THE INTERNET AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON JUNE 10, 2024 We have sent you this Proxy Statement and the enclosed Proxy Card because the board of directors of Terns Pharmaceuticals, Inc. (referred to herein as the “Company,” “Terns,” “we,” “us” or “our”) is soliciting your proxy to vote at our 2024 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on Monday, June 10, 2024, at 9:00 a.m. Pacific Time. The Annual Meeting can be accessed by visiting www.meetnow.global/TERN2024, where you will be able to listen to the meeting live, submit questions and vote online. • This Proxy Statement summarizes information about the proposals to be considered at the Annual Meeting and other information you may find useful in determining how to vote. • The Proxy Card is the means by which you actually authorize another person to vote your shares in accordance with your instructions. In addition to solicitations by mail, our directors, officers and regular employees, without additional remuneration, may solicit proxies by telephone, e-mail and personal interviews. We may retain outside consultants to solicit proxies on our behalf as well. All costs of solicitation of proxies will be borne by us. Brokers, custodians and fiduciaries will be requested to forward proxy soliciting material to the owners of stock held in their names, and we will reimburse them for their reasonable out-of-pocket expenses incurred in connection with the distribution of proxy materials. Pursuant to the rules ad